调和PI-RADS 4病变与靶向活检的不一致:PI-RADS 4亚分类多学科质量改进方案的早期经验
回顾性分析2017年1月至2021年5月接受融合靶向活检的248例患者286个PI-RADS 4病变,采用多学科质量改进方案复核不一致病例。复核后PI-RADS 4对≥GG1和≥GG2病变的阳性预测值分别从0.55和0.34升至0.67和0.43。按ADC值将病变亚分类为高怀疑(4+)和低怀疑(4-)后,两组csPCa检出率分别为61%和17%,提示PI-RADS 4存在异质性。
要点
- PI-RADS 4病变靶向活检病理为良性/GG1时,多学科质量改进复核可提高阳性预测值。
- 按ADC值将PI-RADS 4亚分类为4+和4-,csPCa检出率分别为61%和17%。
- PI-RADS 4+亚组中≥GG1和≥GG2的癌症检出率分别升至75%和61%。
核心结论
- 使用多学科质量改进方案复核PI-RADS 4不一致病例可提高诊断准确性并指导后续管理;该类别存在异质性,PI-RADS 4亚分类可能有价值。
研究设计与样本
- 回顾性研究,纳入2017年1月至2021年5月接受mpMRI融合靶向活检的248例患者共286个PI-RADS 4病变,采用多学科质量改进方案复核不一致靶向活检病理(良性/GG1),并按ADC值对全部病变进行亚分类。
诊断标准与关键数值
- 复核前PI-RADS 4对≥GG1和≥GG2病变的阳性预测值分别为0.55和0.34,复核后分别升至0.67和0.43;按ADC值亚分类为高怀疑(4+)158个和低怀疑(4-)117个病变,逆向融合分析显示分别有61%和17%的病变含csPCa;PI-RADS 4+亚组中≥GG1和≥GG2的癌症检出率分别升至75%和61%。
临床应用与阅片要点
- 作者认为多学科质量改进方案复核PI-RADS 4不一致病例可提高诊断准确性并指导后续管理,并提示PI-RADS 4亚分类可能有价值。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: PI-RADS 4 lesions are considered to have a "high" likelihood of clinically-significant prostate cancer (csPCa). However, patients undergoing targeted biopsy have a range of histologic findings. Understanding discordant cases is critical to improve diagnostic accuracy and inform subsequent management. We studied early findings from implementation of a multidisciplinary Quality Improvement (QI) protocol for reconciling discordance and evaluate the potential heterogeneity of PI-RADS 4.
METHODS: Patients with mpMRI PI-RADS 4 lesions undergoing fusion-targeted biopsy from January 2017 to May 2021 were retrospectively reviewed. The discordant targeted biopsy pathology (benign/GG1) was evaluated utilizing a QI protocol and all lesions were subcategorized based on ADC values. Positive Predictive Value (PPV) for PI-RADS 4 lesions overall and the Cancer Detection Rate (CDR) for subcategorized lesions were calculated.
RESULTS: 248 patients with 286 lesions were reviewed. Prior to re-review, PI-RADS 4 PPV for ≥ GG1 and ≥ GG2 lesions were 0.55 and 0.34, increasing to 0.67 and 0.43 following reconciliation. Lesion subcategorization based on ADC value as higher suspicion (4+) and lower suspicion (4-) resulted in 158 and 117 lesions, with reverse-fusion analysis revealing that 61% and 17% of lesions contained csPCa, respectively. Subgroup analysis among PI-RADS 4+ lesions led to an increase in the CDR to 75% and 61% for ≥ GG1 and ≥ GG2.
CONCLUSION: Use of multidisciplinary QI protocol to review discordance cases of PI-RADS 4 improves diagnostic accuracy and guides subsequent management. Our findings highlight the known heterogeneity of this category with reference to csPCa CDR, suggesting the potential value of PI-RADS 4 subcategorization.
引用
- Deivasigamani, Kotamarti, Adams, et al. Reconciling discordance between PI-RADS 4 lesions and targeted biopsy: Early experience of a multidisciplinary quality improvement protocol with PI-RADS 4 subcategorization. Eur J Radiol. 2023. PMID: 37352682. doi:10.1016/j.ejrad.2023.110929
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。